(a) Proposed research must be submitted to the designated institutional review board (IRB) and contain written information for the IRB to determine whether the requirements described in 45 Code of Federal Regulations (CFR) §46.111 are satisfied.
(b) Each designated IRB shall review all proposed research in accordance with 45 CFR §46.109.
(c) Each designated IRB has the authority to approve, require modifications to, or disapprove any proposed research. Approval of proposed research shall be based on:
(1) consideration of the information described in 45 CFR §46.111;
(2) the designated IRB's verification that the requirements in 45 CFR §46.111, §925.4 of this chapter (relating to General Principles), and §925.8 of this chapter (relating to Informed Consent) are met; and
(3) the designated IRB's verification that procedures for obtaining and documenting authorization to use or disclose protected health information (PHI) meet the requirements in 45 CFR §164.508, unless:
(d) The designated IRB may take into consideration deliberations and reviews from another IRB that has approved the protocol for a specific research proposal, but the designated IRB is ultimately responsible for approval of the proposed research.
(e) Research review and documentation process.
(1) External IRB as the designated IRB. The research review and documentation process for research using an external IRB is generally as follows.
(2) IRB2 as the designated IRB. The research review and documentation process for research involving HHSC services using the IRB2 is generally as follows.
(f) In addition to approval by the designated IRB and HHSC services authorized person, review and approval by the chief medical officer or chief medical director of the state hospitals, state supported living centers, or other entity primarily responsible for the health and safety of the research subjects, as applicable, is required for any research proposal involving:
(1) a placebo as the primary medication therapy;
(2) medication or doses of medication as the primary medication therapy with an unknown effectiveness for the targeted disorder or condition; or
(3) an investigational medication or device.
(g) The review process for proposed research may require additional steps as necessary, (e.g., in the event a proposal is initially rejected).
(h) The HHSC services authorized person is responsible for ensuring that all investigators are qualified to perform any clinical duties assigned to them and are knowledgeable of HHSC's rules governing the care and protection of individuals as described in 25 TAC Chapter 404, Subchapter E (relating to Rights of Persons Receiving Mental Health Services) and 40 TAC Chapter 4, Subchapter C (relating to Rights of Individuals with an Intellectual Disability).
Source Note: The provisions of this §925.7 adopted to be effective November 27, 2022, 47 TexReg 7731